Puma Biotechnology submits sNDA to FDA for Neratinib to treat HER2-positive metastatic breast cancer

This article was originally published here

Neratinib was originally approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer,

The post Puma Biotechnology submits sNDA to FDA for Neratinib to treat HER2-positive metastatic breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply